Lintitript

Drug Profile

Lintitript

Alternative Names: SR 27897

Latest Information Update: 16 Mar 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator sanofi-aventis
  • Class Antiulcers; Indoleacetic acids; Small molecules; Thiazoles
  • Mechanism of Action Cholecystokinin A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Anorexia nervosa; Gastrointestinal disorders; Pancreatic cancer; Psychotic disorders

Most Recent Events

  • 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
  • 03 Oct 2002 Discontinued - Phase-II for Pancreatic cancer in France (PO)
  • 27 Aug 1999 Sanofi has merged with Synthélabo to form Sanofi-Synthélabo
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top